Pirfenidone inhibits carbon tetrachloride- and albumin complex-induced liver fibrosis in rodents by preventing activation of hepatic stellate cells

Clinical and Experimental Pharmacology and Physiology

Volumn 36, Issue 10, 2009, Pages 963-968

  Zhao, Xin Yan ^a   Zeng, Xin ^b,c   Li, Xin Min ^a   Wang, Tai Ling ^d   Wang, Bao En ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b Chinese Academy of Sciences and China National Center for Bioinformation   (China)

^c UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^d CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

Author keywords

Antifibrotic therapy; Fibrosis stage; Human hepatic stellate cells; Liver fibrosis; Pirfenidone

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA SMOOTH MUSCLE ACTIN; ANTIFIBROTIC AGENT; BILIRUBIN; CARBON TETRACHLORIDE; COLLAGEN TYPE 1; HYDROXYPROLINE; MESSENGER RNA; PIRFENIDONE; SILYMARIN; TRANSFORMING GROWTH FACTOR BETA1;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BAGG ALBINO MOUSE; BILIRUBIN BLOOD LEVEL; CELL ACTIVATION; COLORIMETRY; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LIVER FIBROSIS; MALE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; QUANTITATIVE ANALYSIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; STELLATE CELL; TISSUE LEVEL; WISTAR RAT;

ALBUMINS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIGEN-ANTIBODY COMPLEX; CARBON TETRACHLORIDE; CELLS, CULTURED; CYTOPROTECTION; DRUG ANTAGONISM; DRUG EVALUATION, PRECLINICAL; FEMALE; HEPATIC STELLATE CELLS; HUMANS; LIVER CIRRHOSIS; MALE; MICE; MICE, INBRED BALB C; PYRIDONES; RATS; RATS, WISTAR;

EID: 72449202248     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2009.05194.x     Document Type: Article

References (26)

1. Guideline on prevention, and treatment of chronic hepatitis B in China (2005). Chin. Med. J. 2007; 120:2159-2173
2. Keeffe EB, Dieterich DT, Han SH et al. A treatment algorithm for the management of chronic hepatitis B virus infection, in the United States: 2008 update. Clin. Gastroenterol. Hepatol. 2008; 6: 1315-1341
3. Zoulim F, Perrillo R, Hepatitis B. Reflections on the current approach to antiviral therapy. J. Hepatol. 2008; 48 (Suppl 1): S2-19.
4. Lok AS, McMahon. BJ. Chronic hepatitis B. Hepatology 2007; 45: 507-539
5. Friedman. SL. Mechanisms of disease: Mechanisms of hepatic fibrosis and therapeutic implications. Nat. Clin. Pract. Gastroenterol, Hepatol. 2004; 1: 98-105. (Pubitemid 40823677)
6. Tsukada S, Parsons CJ, Rippe RA. Mechanisms of liver fibrosis. Clin. Chim. Acta 2006; 364: 33-60.
7. Okazaki I, Watanabe T, Hozawa S, Niioka M, Arai M, Maruyama K. Reversibility of hepatic fibrosis: From the first report of collagenase in the liver to the possibility of gene therapy for recovery. Keio J. Med. 2001; 50:58-65. (Pubitemid 33611653)
8. Friedman SL. Reversibility of hepatic fibrosis and cirrhosis: Is it all hype? Nat. Clin. Pract. Gastroenterol. Hepatol. 2007; 4: 236-237 (Pubitemid 46711455)
9. Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J. Biol Chem. 2000; 275: 2247-2250
10. Iredale JP. Hepatic stellate cell, behavior during resolution, of liver injury. Semin. Liver Dis. 200.1; 21:427-436
11. Liu X, Hu H, Yin JQ. Therapeutic strategies against TGF-beta signaling pathway in hepatic fibrosis. Liver Int. 2006; 26: 8-22.
12. Lasky J. Pirfenidone. IDrugs 2004; 7: 166-172
13. Garcia L, Hernandez I, Sandoval A et al. Pirfenidone effectively reverses experimental liver fibrosis. J. Hepatol. 2002; 37: 797-805. (Pubitemid 35404219)
14. Tada S, Nakamuta M, Enjoji M et al. Pirfenidone inhibits dimethylnitrosamine-induced hepatic fibrosis in rats. Clin. Exp. Pharmacol. Physiol. 2001; 28: 522-527 (Pubitemid 32588427)
15. Tsuchiya H, Kaibori M, Yanagida H et al. Pirfenidone prevents endotoxin-induced liver injury after partial hepatectomy in rats. J. Hepatol. 2004; 40: 94-101. (Pubitemid 38064717)
16. Armendariz-Borunda J, Islas-Carbajal MC, Meza-Garcia E et al. A pilot study in patients with established advanced liver fibrosis using pirfenidone. Gut 2006; 55: .1663-1665 (Pubitemid 44629221)
17. Constandinou C, Henderson N, Iredale JP. Modeling liver fibrosis in rodents. Methods Mol. Med. 2005; 117:237-250
18. Paronetto F, Popper H. Aggravation of hepatic lesions in mice by in vivo localization of immune complexes (Auer hepatitis). Am. J. Pathol. 1965; 47: 549-563
19. Sun. MA, Wang BE, Annoni G, Degli Esposti S, Biempica L, Zern MA. Two rat models of hepatic fibrosis. A morphologic and molecular comparison. Lab. Invest. 1990; 63:467-475 (Pubitemid 20368726)
20. Reddy GK, Enwemeka CS. A simplified method for the analysis of hydroxyproline in biological tissues. Clin. Biochem. 1996; 29: 225-229 (Pubitemid 26142071)
21. Zhao XY, Wang BE, Wang TL, Li XM. [Inhibitory effects of Silymarin on hepatic fibrosis induced by dimethylnitrosamine: Experiment with rats.] Zhonghua Yi Xue Za Zhi 2006; 86: 2563-2566 (in Chinese).
22. Zhao XY, Wang BE, Li XM, Wang TL. Newly proposed fibrosis staging criterion for assessing carbon tetrachloride- and albumin complex-induced liver fibrosis in. rodents. Pathol. Int. 2008; 58: 580-588
23. Xu L, Hui AY, Albania E et al. Human hepatic stellate cell lines, LX-1 and LX-2: New tools for analysis of hepatic fibrosis. Gut 2005; 54: 142-151 (Pubitemid 40007234)
24. Pfaffl MW. A new mathematical model for relative quantification, in real-time RT-PCR. Nucleic Adds Res. 2001; 29: E45.
25. Salazar-Montes A, Ruiz-Corro L, Lopez-Reyes A, Castrejon-Gomez E, Armendariz-Borunda J. Potent antioxidant role of pirfenidone in experimental, cirrhosis. Eur. J. Pharmacol. 2008; 595: 69-77.
26. Di Sario A, Bendia E, Macarri G et al. The anti-fibrotic effect of pirfenidone in rat liver fibrosis is mediated by downregulation. of procollagen alphal(I): TIMP-1 and MMP-2. Dig. Liver Dis. 2004; 36: 744-751 (Pubitemid 41070596)